Jian Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Jundong Kong
Jinzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Jinzhou 121000, Peoples R China
4 shared publications- Zhongkai Fan
Department of Orthopedics, The First Affiliated Hospital, Jinzhou Medical University, Jinzhou 121000, China
4 shared publications Haohong Zheng
3 shared publicationsQiangqiang Zhang
Jinzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Jinzhou 121000, Peoples R China
3 shared publicationsDiandong Tang
Jinzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Jinzhou 121000, Peoples R China
2 shared publicationsLi Fang
Jinzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Jinzhou 121000, Peoples R China
2 shared publications
Latest Publications
- Open Access
- 20 February 2026
- Published by AccScience Publishing in Orthopedics and Tissue Engineering
- Vol. 1 (2) , 025360015
Immunotherapy in bone and soft-tissue tumors: Current advances and future directions
Immunotherapy has emerged as a transformative strategy for treating bone and soft-tissue sarcomas, a class of rare, heterogeneous malignancies originating from mesenchymal tissues; however, significant challenges remain. This narrative review summarizes recent advances in sarcoma immunotherapy, covering molecular mechanisms, tumor microenvironment (TME) characteristics, and treatment responses specific to major subtypes such as osteosarcoma, liposarcoma, and synovial sarcoma. Notably, despite being a distinct myeloid neoplasm rather than a sarcoma, systemic mastocytosis is included in this study to identify common therapeutic targets through cross-disease comparisons (e.g., kinase-driven pathways and mechanisms regulating the immunosuppressive TME). Clinical data indicate that single-agent immune checkpoint inhibitors (ICIs) produce limited objective response rates in advanced sarcomas (approximately 16.7%), with significant efficacy disparities across subtypes, ranging from high response rates in alveolar soft part sarcomas to minimal responses in osteosarcomas. Key resistance mechanisms include a suppressive TME dominated by myeloid-derived suppressor cells, low tumor mutational burden, and antigenic heterogeneity. Combination strategies such as ICIs with radiotherapy, tyrosine kinase inhibitors, or anti-angiogenic agents significantly improve outcomes. Emerging cell therapies such as chimeric antigen receptor T-cell, T-cell receptor–engineered, and tumor-infiltrating lymphocyte therapies, combined with neoantigen vaccines and nanotechnology-driven delivery systems, demonstrate potential in reshaping the TME and overcoming immune escape. Biomarkers, including programmed death-ligand 1 expression, tertiary lymphoid structures, and immune gene profiles, hold prognostic value but require further validation. Future research should prioritize tissue-specific trial designs, combined TME remodeling regimens, and biomarker-guided personalized therapies to effectively convert “cold” sarcomas into immunotherapy-responsive malignancies.
- 20 February 2026
- Published by AccScience Publishing in Orthopedics and Tissue Engineering
- Vol. 1 (2) , 025360015
Open AccessImmunotherapy in bone and soft-tissue tumors: Current advances and future directions
Immunotherapy has emerged as a transformative strategy for treating bone and soft-tissue sarcomas, a class of rare, heterogeneous malignancies originating from mesenchymal tissues; however, significant challenges remain. This narrative review summarizes recent advances in sarcoma immunotherapy, covering molecular mechanisms, tumor microenvironment (TME) characteristics, and treatment responses specific to major subtypes such as osteosarcoma, liposarcoma, and synovial sarcoma. Notably, despite being a distinct myeloid neoplasm rather than a sarcoma, systemic mastocytosis is included in this study to identify common therapeutic targets through cross-disease comparisons (e.g., kinase-driven pathways and mechanisms regulating the immunosuppressive TME). Clinical data indicate that single-agent immune checkpoint inhibitors (ICIs) produce limited objective response rates in advanced sarcomas (approximately 16.7%), with significant efficacy disparities across subtypes, ranging from high response rates in alveolar soft part sarcomas to minimal responses in osteosarcomas. Key resistance mechanisms include a suppressive TME dominated by myeloid-derived suppressor cells, low tumor mutational burden, and antigenic heterogeneity. Combination strategies such as ICIs with radiotherapy, tyrosine kinase inhibitors, or anti-angiogenic agents significantly improve outcomes. Emerging cell therapies such as chimeric antigen receptor T-cell, T-cell receptor–engineered, and tumor-infiltrating lymphocyte therapies, combined with neoantigen vaccines and nanotechnology-driven delivery systems, demonstrate potential in reshaping the TME and overcoming immune escape. Biomarkers, including programmed death-ligand 1 expression, tertiary lymphoid structures, and immune gene profiles, hold prognostic value but require further validation. Future research should prioritize tissue-specific trial designs, combined TME remodeling regimens, and biomarker-guided personalized therapies to effectively convert “cold” sarcomas into immunotherapy-responsive malignancies.
- 20 October 2024
- Published by Elsevier in Experimental Neurology
- Vol. 383, 114998
Corrigendum to “TGN-020 ameliorates motor dysfunction post-spinal cord injury via enhancing astrocyte autophagy and mitigating inflammation by activating AQP4/PPAR-γ/mTOR pathway” [Experimental Neurology volume 382 (2024) 114975]
- 20 October 2024
- Published by Elsevier in Experimental Neurology
- Vol. 383, 114998
Corrigendum to “TGN-020 ameliorates motor dysfunction post-spinal cord injury via enhancing astrocyte autophagy and mitigating inflammation by activating AQP4/PPAR-γ/mTOR pathway” [Experimental Neurology volume 382 (2024) 114975]
- 24 September 2024
- Published by Elsevier in Experimental Neurology
- Vol. 382, 114975
TGN-020 ameliorates motor dysfunction post-spinal cord injury via enhancing astrocyte autophagy and mitigating inflammation by activating AQP4/PPAR-γ/mTOR pathway
- 24 September 2024
- Published by Elsevier in Experimental Neurology
- Vol. 382, 114975
TGN-020 ameliorates motor dysfunction post-spinal cord injury via enhancing astrocyte autophagy and mitigating inflammation by activating AQP4/PPAR-γ/mTOR pathway
- 31 October 2022
- Published by Elsevier in Neuroscience Research
- Vol. 188, 39-50
miR‑222-3p reduces neuronal cell apoptosis and alleviates spinal cord injury by inhibiting Bbc3 and Bim
- 31 October 2022
- Published by Elsevier in Neuroscience Research
- Vol. 188, 39-50
miR‑222-3p reduces neuronal cell apoptosis and alleviates spinal cord injury by inhibiting Bbc3 and Bim
- 15 September 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 190, 12-21
Upregulation of TRPC6 inhibits astrocyte activation and proliferation after spinal cord injury in rats by suppressing AQP4 expression
- 15 September 2022
- Published by Elsevier in Brain Research Bulletin
- Vol. 190, 12-21
Upregulation of TRPC6 inhibits astrocyte activation and proliferation after spinal cord injury in rats by suppressing AQP4 expression